Patents by Inventor Daniel TARJAN

Daniel TARJAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11339442
    Abstract: The present application generally to the diagnosis and treatment of diseases resulting from the alteration of chromatin boundaries between topologically-associated domains. In particular, the present application relates to detection of mutations causing DNA hypermethylation phenotypes, CpG methylation within CTCF binding motifs, and aberrant gene expression caused by altered chromatin topology. Applicants show that IDH mutant gliomas exhibit hyper-methylation at CTCF binding sites, compromising binding of this methylation-sensitive insulator protein. Applicants also demonstrate that loss of CTCF at a domain boundary permits a constitutive enhancer to aberrantly interact with the receptor tyrosine kinase gene PDGFRA, a prominent glioma oncogene. Thus, Applicants have uncovered that IDH mutations may promote gliomagenesis by disrupting chromosomal topology and allowing aberrant regulatory interactions that induce oncogene expression.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: May 24, 2022
    Assignee: The General Hospital Corporation
    Inventors: Bradley Bernstein, Yotam Drier, William Flavahan, Daniel Tarjan
  • Publication number: 20200224274
    Abstract: The present application generally to the diagnosis and treatment of diseases resulting from the alteration of chromatin boundaries between topologically-associated domains. In particular, the present application relates to detection of mutations causing DNA hypermethylation phenotypes, CpG methylation within CTCF binding motifs, and aberrant gene expression caused by altered chromatin topology. Applicants show that IDH mutant gliomas exhibit hyper-methylation at CTCF binding sites, compromising binding of this methylation-sensitive insulator protein. Applicants also demonstrate that loss of CTCF at a domain boundary permits a constitutive enhancer to aberrantly interact with the receptor tyrosine kinase gene PDGFRA, a prominent glioma oncogene. Thus, Applicants have uncovered that IDH mutations may promote gliomagenesis by disrupting chromosomal topology and allowing aberrant regulatory interactions that induce oncogene expression.
    Type: Application
    Filed: December 14, 2016
    Publication date: July 16, 2020
    Inventors: Bradley Bernstein, Yotam Drier, William Flavahan, Daniel Tarjan
  • Publication number: 20160208323
    Abstract: Disclosed are methods for shearing and tagging chromatin DNA. The disclosed methods include contacting chromatin DNA with at least one transposome, that includes a transposase enzyme. The transposon is made up of a first DNA molecule that includes a first transposase recognition site and a second DNA molecule that includes a second transposase recognition site, wherein the transposase integrates the first and second DNA molecules into chromatin DNA. The first and second DNA molecules of the transposon can be disconnected, such that upon integration of the transposon the chromatin bound DNA is sheared and tagged with the first and second DNA molecules, for example to prepare a library of sheared and tagged chromatin DNA fragments.
    Type: Application
    Filed: June 19, 2014
    Publication date: July 21, 2016
    Inventors: Bradley BERNSTEIN, Alon GOREN, Chad NUSBAUM, Oren RAM, Assaf ROTEM, Daniel TARJAN, Jeffrey XING, Aviv REGEV